Vyriad, Inc.

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sarepta Obtains Rights To Seven Arrowh

The global non-profit Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), which provides funding and other support for early-stage development of treatments, diagnostics an

Raquel Deering knew she wanted to be a scientist as a young child. When she was 14, she called Paige Kaplan, a medical geneticist at The Children's Hospital of Philadelphia, and asked to visit to talk